^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    PGR expression

    i
    Entrez ID:
    5241
    Related biomarkers:
    Expression
    Mutation
    Others
    Related tests:
    Apply
    Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery (NCT04609592)
    Phase 1
    Stanford University
    Recruiting
    Last update posted :
    10/28/2024
    Initiation :
    03/17/2021
    Primary completion :
    03/01/2025
    Completion :
    09/01/2027
    SSTR
    |
    PGR expression
    |
    Lutathera (lutetium Lu 177 dotatate)
    CFI-400945 and Durvalumab in Patients With Advanced Triple Negative Breast Cancer (NCT04176848)
    Phase 2
    Canadian Cancer Trials Group
    Active, not recruiting
    Last update posted :
    08/09/2024
    Initiation :
    08/10/2020
    Primary completion :
    09/15/2022
    Completion :
    12/31/2024
    HER-2 • ER • PGR • PLK4
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    Imfinzi (durvalumab) • ocifisertib (CFI-400945)
    Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer (NCT02530489)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    02/04/2016
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    HER-2 • ER • PGR
    |
    HER-2 amplification • HER-2 negative • PGR expression
    |
    Tecentriq (atezolizumab) • albumin-bound paclitaxel
    Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) (NCT04862663)
    Phase 3
    AstraZeneca
    Recruiting
    Last update posted :
    06/06/2024
    Initiation :
    05/10/2021
    Primary completion :
    11/01/2027
    Completion :
    08/14/2029
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR expression
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • Truqap (capivasertib)
    Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab (NCT05877859)
    Phase N/A
    Emory University
    Recruiting
    Last update posted :
    05/31/2024
    Initiation :
    05/30/2023
    Primary completion :
    04/10/2025
    Completion :
    04/10/2026
    HER-2 • ER • PGR • IFNG • IL6 • TGFB1 • IFNA1
    |
    HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    Keytruda (pembrolizumab)
    Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors (NCT03911453)
    Phase 1
    University of Arizona
    Active, not recruiting
    Last update posted :
    05/31/2024
    Initiation :
    04/19/2019
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    HER-2 • PD-L1 • ER • PGR • PD-1
    |
    PD-L1 expression • HER-2 expression • HRD • PGR expression
    |
    Rubraca (rucaparib)
    Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer (ISIdE) (NCT05552001)
    Phase 3
    UNICANCER
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    10/05/2023
    Primary completion :
    12/01/2024
    Completion :
    05/01/2026
    HER-2 • ER • PGR • PD-1
    |
    ER expression • PGR expression • ER amplification • PD-1 positive
    |
    Trodelvy (sacituzumab govitecan-hziy)
    A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) (NCT06100874)
    Phase 2
    Adrienne G. Waks
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    11/20/2023
    Primary completion :
    11/30/2026
    Completion :
    11/30/2027
    HER-2
    |
    PGR expression
    |
    Herceptin (trastuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trodelvy (sacituzumab govitecan-hziy) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)
    HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease (TUXEDO-3) (NCT05865990)
    Phase 2
    MedSIR
    Recruiting
    Last update posted :
    05/16/2024
    Initiation :
    11/24/2023
    Primary completion :
    12/31/2025
    Completion :
    10/01/2026
    HER-2 • ER • PGR • ERBB3 • TACSTD2
    |
    HER-2 positive • EGFR mutation • HER-2 expression • EGFR T790M • ERBB3 expression • TROP2 expression • ER expression • PGR expression
    |
    patritumab deruxtecan (U3-1402)
    STEMVAC in Patients With Early Stage Triple Negative Breast Cancer (NCT05455658)
    Phase 2
    University of Washington
    Recruiting
    Last update posted :
    05/08/2024
    Initiation :
    11/17/2022
    Primary completion :
    04/30/2025
    Completion :
    12/31/2025
    HER-2 • ER • PGR • IFNG
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    EP-101 STEMVAC • Leukine (sargramostim)
    Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer (NCT02876107)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    04/05/2024
    Initiation :
    10/06/2016
    Primary completion :
    10/31/2025
    Completion :
    10/31/2025
    HER-2 • NODAL
    |
    HER-2 negative • HER-2 expression • PGR expression
    |
    carboplatin • paclitaxel • Vectibix (panitumumab) • doxorubicin hydrochloride • cyclophosphamide
    Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer (NCI-2016-01913) (NCT02996825)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/02/2024
    Initiation :
    03/22/2017
    Primary completion :
    02/09/2024
    Completion :
    02/09/2024
    HER-2 • ER • PGR • MUC16
    |
    HER-2 negative • PGR expression
    |
    gemcitabine • Elahere (mirvetuximab soravtansine-gynx) • liposomal gemcitabine (FF-10832)
    A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (NCT04613674)
    Phase 3
    Jiangsu HengRui Medicine Co., Ltd.
    Completed
    Last update posted :
    03/27/2024
    Initiation :
    12/09/2020
    Primary completion :
    09/14/2023
    Completion :
    03/05/2024
    HER-2
    |
    HER-2 expression • PGR expression
    |
    AiRuiKa (camrelizumab)
    A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) (NCT03125902)
    Phase 3
    Hoffmann-La Roche
    Completed
    Last update posted :
    03/26/2024
    Initiation :
    08/25/2017
    Primary completion :
    11/15/2019
    Completion :
    01/17/2023
    HER-2 • ER • PGR
    |
    PGR expression
    |
    Tecentriq (atezolizumab) • paclitaxel
    Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS) (NCT04383275)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    08/23/2021
    Primary completion :
    05/15/2025
    Completion :
    05/15/2027
    HER-2
    |
    HER-2 positive • HR positive • HER-2 amplification • ER negative • PGR expression • PGR negative
    |
    Herceptin (trastuzumab) • tamoxifen • capecitabine
    Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer (NCT05861271)
    Phase 2
    Fudan University
    Recruiting
    Last update posted :
    03/22/2024
    Initiation :
    06/01/2023
    Primary completion :
    07/01/2026
    Completion :
    07/01/2028
    HER-2
    |
    HER-2 positive • HER-2 amplification • HR negative • PGR expression
    |
    tamoxifen • capecitabine • Irene (pyrotinib) • exemestane
    Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer (OATH) (NCT04719273)
    Phase 2
    Thomas Jefferson University
    Active, not recruiting
    Last update posted :
    03/13/2024
    Initiation :
    01/28/2021
    Primary completion :
    12/31/2024
    Completion :
    12/31/2024
    ER • PGR
    |
    PGR expression
    |
    anastrozole • Apristor (onapristone XR)
    Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) (NCT04109066)
    Phase 3
    Bristol-Myers Squibb
    Completed
    Last update posted :
    03/12/2024
    Initiation :
    11/20/2019
    Primary completion :
    01/16/2023
    Completion :
    12/27/2023
    HER-2 • ER • PGR
    |
    ER positive • PGR expression
    |
    Opdivo (nivolumab) • paclitaxel • cyclophosphamide
    HER2(Human Epidermal Growth Factor Receptor 2) -Positive Metastatic Breast Cancer in Russia (NCT05905939)
    Phase N/A
    AstraZeneca
    Recruiting
    Last update posted :
    03/07/2024
    Initiation :
    05/31/2023
    Primary completion :
    06/21/2024
    Completion :
    06/21/2024
    HER-2 • ER • PGR
    |
    HER-2 positive • PGR expression
    Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer (BELLA) (NCT04739670)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Recruiting
    Last update posted :
    03/01/2024
    Initiation :
    03/01/2021
    Primary completion :
    09/01/2025
    Completion :
    09/30/2025
    PD-L1 • ER • PGR
    |
    PD-L1 expression • ER expression • PGR expression
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • gemcitabine
    Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer (NCT06105008)
    Phase 2
    RemeGen Co., Ltd.
    Not yet recruiting
    Last update posted :
    02/21/2024
    Initiation :
    12/20/2024
    Primary completion :
    12/20/2025
    Completion :
    04/10/2026
    HER-2 • ER
    |
    HER-2 expression • HER-2 underexpression • PGR expression
    |
    Loqtorzi (toripalimab-tpzi) • Aidixi (disitamab vedotin)
    A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) (NCT05999149)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/21/2024
    Initiation :
    08/20/2023
    Primary completion :
    08/30/2025
    Completion :
    08/30/2027
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • AiRuiKa (camrelizumab) • albumin-bound paclitaxel • famitinib (SHR 1020)
    Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer (NCT02971761)
    Phase 2
    City of Hope Medical Center
    Completed
    Last update posted :
    02/19/2024
    Initiation :
    06/01/2017
    Primary completion :
    10/28/2020
    Completion :
    08/16/2022
    HER-2 • ER • PGR • AR
    |
    HER-2 negative • AR positive • ER expression • PGR expression
    |
    Keytruda (pembrolizumab) • Ostarine (enobosarm)
    Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer (KEYNOTE 721) (NCT03310957)
    Phase 1/2
    Seagen Inc.
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    02/27/2018
    Primary completion :
    03/31/2024
    Completion :
    12/31/2024
    HER-2 • PD-L1
    |
    HER-2 expression • PGR expression
    |
    Keytruda (pembrolizumab) • ladiratuzumab vedotin (SGN-LIV1A)
    Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer (BCTOP-T-M01) (NCT05806060)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/08/2024
    Initiation :
    04/25/2023
    Primary completion :
    08/31/2025
    Completion :
    02/28/2026
    HER-2
    |
    HER-2 expression • PGR expression
    |
    Avastin (bevacizumab) • carboplatin • capecitabine • albumin-bound paclitaxel • Halaven (eribulin mesylate) • vinorelbine tartrate
    Examining Bioactivity of PVSRIPO in Invasive Breast Cancer (NCT03564782)
    Phase 1
    Istari Oncology, Inc.
    Completed
    Last update posted :
    02/08/2024
    Initiation :
    06/30/2019
    Primary completion :
    04/11/2022
    Completion :
    04/11/2022
    HER-2 • ER • PGR
    |
    HER-2 amplification • HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    lerapolturev (PVS-RIPO)
    Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. (BCTOP-T-M02) (NCT05760378)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    02/06/2024
    Initiation :
    03/17/2023
    Primary completion :
    01/01/2025
    Completion :
    01/01/2027
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • AiRuiKa (camrelizumab) • capecitabine • Halaven (eribulin mesylate) • famitinib (SHR 1020)
    Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer (NCT03012230)
    Phase 1
    Mayo Clinic
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    12/06/2017
    Primary completion :
    01/06/2023
    Completion :
    03/08/2023
    HER-2 • PD-L1 • ER • PGR • JAK2 • PD-L2
    |
    PD-L1 expression • PD-L1 amplification • PGR expression
    |
    Keytruda (pembrolizumab) • Jakafi (ruxolitinib)
    PhI to Solid Tumors and PhII to Locally Advanced or mTNBC (NCT05390710)
    Phase 1
    Laekna Limited
    Completed
    Last update posted :
    01/31/2024
    Initiation :
    06/12/2021
    Primary completion :
    12/11/2023
    Completion :
    12/11/2023
    HER-2 • PD-L1 • ER • PGR • PTEN • BRCA • PI3K
    |
    PD-L1 expression • PGR expression
    |
    albumin-bound paclitaxel • afuresertib (LAE002) • LAE005
    A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA) (NCT03215706)
    Phase 3
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    01/10/2024
    Initiation :
    08/24/2017
    Primary completion :
    08/16/2019
    Completion :
    01/19/2026
    PD-L1
    |
    PD-L1 expression • PGR expression
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • paclitaxel • pemetrexed
    Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial (NCT04756505)
    Phase 1
    M.D. Anderson Cancer Center
    Withdrawn
    Last update posted :
    12/27/2023
    Initiation :
    03/07/2021
    Primary completion :
    02/16/2022
    Completion :
    02/16/2022
    HER-2 • ER
    |
    HER-2 amplification • HER-2 negative • PGR expression
    |
    bintrafusp alfa (M7824) • PDS01ADC
    An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. (FUTURE-SUPER) (NCT04395989)
    Phase 2
    Fudan University
    Active, not recruiting
    Last update posted :
    12/22/2023
    Initiation :
    07/28/2020
    Primary completion :
    05/31/2023
    Completion :
    12/31/2024
    HER-2
    |
    HER-2 expression • PGR expression
    |
    Avastin (bevacizumab) • everolimus • AiRuiKa (camrelizumab) • capecitabine • Irene (pyrotinib) • albumin-bound paclitaxel • famitinib (SHR 1020) • Airuituo (bevacizumab biosimilar)
    Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS (TILS001) (NCT05451784)
    Phase 1/2
    Fundacio Clinic Barcelona
    Recruiting
    Last update posted :
    11/24/2023
    Initiation :
    07/20/2022
    Primary completion :
    11/30/2025
    Completion :
    09/30/2027
    HER-2 • PD-1
    |
    HER-2 negative • PD-1 expression • PGR expression
    |
    NUMARZU-001
    Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer (NCT02672475)
    Phase 1
    Vanderbilt-Ingram Cancer Center
    Completed
    Last update posted :
    11/22/2023
    Initiation :
    03/01/2016
    Primary completion :
    04/01/2021
    Completion :
    08/01/2023
    HER-2 • ER • PGR
    |
    HER-2 negative • HER-2 expression • ER negative • PGR expression • PGR negative
    |
    paclitaxel • galunisertib (LY2157299)
    OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer (NCT05949021)
    Phase 2
    Mridula George, MD
    Recruiting
    Last update posted :
    11/17/2023
    Initiation :
    10/07/2023
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    HER-2 • ER • PGR
    |
    ER expression • PGR expression
    |
    carboplatin
    Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) (NCT04296175)
    Phase 3
    Fudan University
    Recruiting
    Last update posted :
    11/14/2023
    Initiation :
    03/05/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2025
    HER-2
    |
    HER-2 expression • PGR expression
    |
    carboplatin • paclitaxel • epirubicin
    A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors (NCT05866692)
    Phase 1
    TYK Medicines, Inc
    Recruiting
    Last update posted :
    11/06/2023
    Initiation :
    08/17/2023
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    HER-2 • PD-L1 • KRAS • ER • BRCA
    |
    KRAS mutation • HER-2 negative • ER negative • BRCA mutation • PGR expression
    |
    TY-2699a
    Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in Metastatic Triple Negative Breast Cancer (MIMIR-mTNBC) (NCT05742269)
    Phase N/A
    Karolinska University Hospital
    Recruiting
    Last update posted :
    10/04/2023
    Initiation :
    07/01/2023
    Primary completion :
    12/31/2026
    Completion :
    05/20/2027
    HER-2 • PD-L1 • ER • PGR
    |
    HER-2 negative • HER-2 expression • ER expression • PGR expression
    |
    Tecentriq (atezolizumab) • carboplatin • albumin-bound paclitaxel